Long Remissions After Late Relapse of Acute Myeloid Leukaemia (AML) with Idarubicin + Cytarabine Conventional Doses Treatment

The main purpose of treatment of acute leukaemia is a selection of patients who are potentially curable by appropriate therapy. Relapsed acute leukaemia still remains often an incurable disease. However there is a late relapse group within AML patients (pts) whose prognosis is not so bad. Idarubicin, antileukaemic drug, was investigated in late 1970′s with phase 1 clinical trial in 1980 (Casazza et al. 1980). Later its activity in relapsed and refractory acute leukaemia was found (Kaplan et al. 1982). We report herein the results of the treatment of primary resistant and early and late relapsed AML with salvage regimen containing Idarubicin.